Every material Form 8-K Prestige Consumer Healthcare filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Prestige Consumer Healthcare reported fiscal second-quarter 2026 revenue of $274.1 million, down 3.4% from a year earlier, mainly due to limited ability to supply Clear Eyes. GAAP diluted EPS fell to $0.86 from $1.09, and adjusted diluted EPS was $1.07 versus $1.09. The company narrowed its fiscal 2026 adjusted EPS outlook to $4.54 to $4.58 from $4.50 to $4.58, while its revenue outlook was unchanged.
Q2 revenue $274.1 million vs. $283.8 million a year earlier; GAAP net income $42.2 million vs. $54.4 million
Q2 diluted EPS $0.86 (GAAP) and $1.07 (adjusted), vs. $1.09 in the prior-year quarter
Fiscal 2026 adjusted diluted EPS outlook $4.54 to $4.58, up from $4.50 to $4.58; revenue outlook $1,100 to $1,115 million unchanged
Repurchased about 1.1 million shares for about $75.0 million in Q2; net debt about $0.9 billion
Prestige Consumer Healthcare reported first-quarter fiscal 2026 revenue of $249.5 million, down 6.6% from $267.1 million a year earlier, citing limited supply of Clear Eyes. It lowered its fiscal 2026 revenue and diluted EPS outlook and agreed to buy Pillar5 Pharma, its Clear Eyes supplier, for CAD 150 million in cash, subject to adjustments. The lower outlook reflects expected eye care supply shortfalls in the first half, and the acquisition is intended to secure supply, though closing depends on conditions and is expected in the third quarter of fiscal 2026.
Q1 fiscal 2026 revenue of $249.5 million, down 6.6% from $267.1 million; diluted EPS of $0.95 versus $0.98 a year earlier and $0.90 adjusted
Fiscal 2026 revenue outlook cut to $1,100 million to $1,115 million from $1,140 million to $1,155 million
Fiscal 2026 diluted EPS outlook cut to $4.50 to $4.58 from $4.70 to $4.82; free cash flow outlook of $245 million or more unchanged
Pillar5 Pharma acquisition for CAD 150 million in cash, expected to close in fiscal third quarter 2026 subject to conditions
Prestige Consumer Healthcare reported higher fourth-quarter and full-year fiscal 2025 revenue and diluted earnings per share versus the prior year, and gave initial fiscal 2026 guidance of $1,140 million to $1,155 million in revenue and $4.70 to $4.82 in diluted EPS. The company also recorded a $12.5 million non-cash tradename impairment in the quarter, which it said relates to non-strategic brands, and cited an expected approximately $15 million tariff-related headwind for fiscal 2026.
Q4 fiscal 2025 revenue of $296.5 million rose 7.0% from $277.0 million; diluted EPS was $1.00 versus $0.98
Fiscal 2025 revenue of $1,137.8 million rose 1.1%; diluted EPS was $4.29 versus $4.17, and adjusted diluted EPS was $4.52 versus $4.21
Fiscal 2026 outlook: revenue of $1,140 million to $1,155 million, diluted EPS of $4.70 to $4.82, and free cash flow of $245 million or more
Q4 included a $12.5 million tradename impairment; leverage was 2.4x at March 31, 2025
Prestige Consumer Healthcare reported third-quarter fiscal 2025 revenue of $290.3 million, up 2.7%, with diluted EPS of $1.22 versus $1.06 a year earlier. The company raised its fiscal 2025 adjusted diluted EPS outlook to approximately $4.50 from $4.40 to $4.46, and narrowed its revenue outlook to $1,128 million to $1,132 million. Nine-month revenue declined 0.8%, and third-quarter free cash flow fell, so shareholders gain from higher earnings guidance but see mixed trends in sales and cash flow.
Q3 revenue $290.3 million, up 2.7% from $282.7 million; diluted EPS $1.22 versus $1.06
Nine-month revenue $841.2 million, down 0.8%; non-GAAP adjusted diluted EPS $3.20 versus $3.19
FY2025 adjusted diluted EPS outlook raised to approximately $4.50 from $4.40 to $4.46; revenue outlook $1,128 million to $1,132 million
Q3 non-GAAP free cash flow $63.5 million versus $69.5 million; net debt about $0.9 billion, leverage 2.5x
Prestige Consumer Healthcare said Chief Financial Officer Christine Sacco's role has been expanded to include Chief Operating Officer, effective immediately, and she will oversee the company's supply chain while continuing as CFO. The filing sets out her compensation for the expanded role, including a $700,000 base salary and a $1,575,000 retention RSU award, which shareholders may track in future proxy disclosures.
Sacco, 49, has been CFO since September 2016 and will now serve as COO/CFO, reporting to CEO Ron Lombardi
Annual base salary of $700,000; target annual cash incentive of 75% of base salary
Targeted annual equity award of $1,575,000, split 60% performance stock units and 40% restricted stock units
Time-based RSU retention award with an aggregate value of $1,575,000, cliff vesting four years after grant
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Prestige Consumer Healthcare filing is on SEC EDGAR ↗. 8-K briefs of other companies →